EACR-AACR Basic and Translational Research Conference
In partnership with IACR (Irish Association for Cancer Research)

How to Bring Basic Science Discoveries to the Clinic



The European Association for Cancer Research (EACR) and American Association for Cancer Research (AACR) are proud to continue their Basic and Translational Research Conference series with this new joint conference in Dublin, Ireland in collaboration with the Irish Association for Cancer Research (IACR).

Gathering top experts in the fields of immunology, drug development, tumour microenvironment, genomics and epigenetics, this Joint Conference will focus on bringing the latest discoveries from basic science to the clinic. The forum will highlight the latest cutting-edge advances in the understanding of the genomics, epigenetics and molecular pathways involved in the development of pre-cancerous and cancerous lesions and/ or in cancer response to therapy. The scientific programme blends basic and translational research from preclinical models to patients.


Cancer is caused by a complex interaction between inherited genetics, acquired somatic mutations, epigenetic changes and environmental factors. Genetic and epigenetic changes alter the competitive fitness of normal, stem and/ or progenitor cells giving them the ability to grow uncontrollably and spread. However, cancers develop in complex tissue environments, which they depend upon for progression and metastasis and cancer development is further modulated by the immune response. Understanding how reciprocal communication between cancer cells, the immune and stromal cells controls tumour development and modulates the response to therapeutic intervention is key for progressing cancer care. Moreover, a series of new, exciting studies have recently investigated the effects of conventional chemotherapy and immunotherapy uncovering unanticipated additional modes of action and unforeseen cellular effects. Altogether this opens novel opportunities for mechanism-based combinations, the discovery of novel drug targets and the development of new drugs.

Target Audience

The target audience for this conference is basic and translational scientists, including experienced investigators and trainees at all levels with an interest in cancer development and treatment, as well as clinicians involved in the development of novel therapeutic approaches to treatment.

Topics to be covered:

  • Immunotherapy / Immuno-Oncology
  • Cell Based Therapies
  • Novel Targets / Undruggable Targets
  • Drug Combinations
  • Drug Resistance
  • The Precancer Genome
  • Liquid Biopsies
  • Preclinical Models
  • Tumour Microenvironment
  • Epigenetics



The year of the conference marks IACR’s 60th anniversary.

Key dates

Open for full rate registrations from:
27 January 2024

Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available

Follow along on social media and engage with the event using #EAISciencetoClinic

Above: the beautiful venue city of Dublin

Scientific Programme Committee


  • Rene Bernards (Co-Chair EACR)
  • Christine M. Lovly (Co-Chair AACR)
  • Tracy Robson (Co-Chair IACR)

Committee members

  • Hugues de The
  • Maria Soengas
  • Luis A. Diaz
  • Crystal L. Mackall
  • Niamh Lynam-Lennon
  • Alex Eustace

Sorry. You need to upgrade your browser

You are using Internet Explorer 8

This is considered an out of date browser. This website has been developed with modern browsers in mind to allow it to display at its best in a wide variety of viewing situations - including mobile viewing. But we haven't supported older browsers like IE8. Please upgrade to the latest version of Internet Explorer - or try Mozilla Firefox or Google Chrome. Both are excellent browsers.

Thank you.